Loading...

Cigna Thalomid Coverage Update Prior Auth | OpenPayer

ModifiedCignaPolicy IP0493

Thalomid

This policy governs prior-authorization and medical necessity criteria for coverage of Thalomid (thalidomide capsules) under Cigna-administered health benefit plans; it applies to providers requesting coverage for listed indications and to patients receiving Thalomid.

Policy Summary

PayerCigna

PolicyThalomid

Policy CodePolicy IP0493

Change TypeAnnual revision — added FDA indication and other uses

Effective DateAug 15, 2025

Next Review Date

Key ActionSubmit prior authorization requests with appropriate supporting documentation and covered diagnosis codes for Thalomid; approvals are typically for 1 year.

SourceLink

POLICY UPDATE CHANGES

Added criteria for Multiple Myeloma as an FDA-approved indication.

Changed statement on Crohn's disease from 'do not mention Thalomid' to noting ACG says thalidomide may be effective only in exceptional circumstances due to high risk of severe adverse effects.

Added criteria for Castleman Disease, Histiocytic Neoplasms, Kaposi Sarcoma, and Medulloblastoma as Other Uses with Supportive Evidence.

Updated formatting to examples of alternatives and adjusted 'tried' criteria wording.

Updated title from 'Oncology - Thalomid for Non- Oncology Uses' to 'Oncology - Thalomid'.

9indications listed as medically necessary when criteria met

1 yeartypical approval duration

Prior Authcoverage requirement

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Criteria for Thalomid (thalidomide)

Initial and Approved Indications

Thalomid is considered medically necessary when ONE of the following is met:

Erythema Nodosum Leprosum (ENL): Erythema Nodosum Leprosum: Approve for 1 year.

FDA indication

Castleman Disease: Approve for 1 year if the patient has relapsed/refractory or progressive disease OR meets BOTH of: multicentric disease AND is negative for HIV and HHV-8.

Other use with supportive evidence

Discoid/Cutaneous Lupus: Approve for 1 year if the patient has tried at least two other medications (examples: corticosteroids, antimalarials, topical calcineurin inhibitors, azathioprine, cyclosporine, mycophenolate mofetil, methotrexate, dapsone, acitretin).

Other use with supportive evidence

Kaposi Sarcoma: Patient has tried at least one medication (examples: liposomal doxorubicin, paclitaxel, pomalidomide, lenalidomide, imatinib) AND patient has relapsed or refractory disease; Approve for 1 year.

Other use with supportive evidence

Medulloblastoma (pediatric): Patient is < 18 years of age AND has recurrent or progressive disease AND the medication is being used as part of the MEMMAT regimen; Approve for 1 year.

Other use with supportive evidence; regimen-specified

Prurigo Nodularis: Approve for 1 year if the patient has tried at least two other medications (examples: topical/intralesional/systemic steroids, cyclosporine, macrolides, azathioprine, methotrexate, topical calcineurin inhibitors, retinoids, antihistamines, dapsone, capsaicin, phototherapy).

Other use with supportive evidence

Recurrent Aphthous Ulcers / Aphthous Stomatitis: Approve for 1 year if the patient has tried at least two other medications (examples: topical or intralesional corticosteroids, systemic corticosteroids, topical anesthetics, antimicrobial mouthwashes, topical sucralfate, acyclovir, pentoxifylline, dapsone, colchicine, azathioprine).

Other use with supportive evidence

Coverage updates

Policy updates and coverage stance changes summarized

FDA-approved oncology indications: Added criteria for Multiple Myeloma as an FDA-approved indication.

See full policy for detailed criteria

Other supported uses

Other Uses with Supportive Evidence

Other supported conditions: Criteria added for Castleman Disease, Histiocytic Neoplasms, Kaposi Sarcoma, Medulloblastoma, discoid/cutaneous lupus, prurigo nodularis, and recurrent aphthous ulcers when condition-specific requirements are met.

See full policy sections for condition-specific requirements

Thalomid (thalidomide) for indications not specifically listed as covered in this policy is considered not medically necessary. Examples explicitly called out include use for cancer cachexia, where existing studies are small and limited, and a published review concluded there is inadequate evidence to recommend Thalomid for management of cancer-related cachexia in clinical practice.

Requests for Thalomid for Crohn’s disease are listed under Conditions Not Covered. The evidence base consists primarily of small, low-quality reports (case series, open-label and retrospective studies, often in pediatric or refractory populations) and lacks randomized, controlled trial data. The American College of Gastroenterology (2018) notes thalidomide may be effective only in exceptional circumstances for severe Crohn’s disease and cautions about the high risk of serious adverse effects; the policy was updated to reflect this guideline context.

The rationale for deeming Thalomid use in cancer cachexia not medically necessary is the inadequate and inconsistent evidence base. Although a few small trials and studies have evaluated thalidomide in cancer-related weight loss, results are limited by small sample sizes and study design, and a published review concluded there is insufficient evidence to support routine clinical use; therefore the policy does not cover this indication.

The policy’s determination that Thalomid is not medically necessary for Crohn’s disease is grounded in the low quality of available data and guideline recommendations. Published reports are mostly open-label or retrospective with few patients, and both ACG guidance (2018) and other society statements emphasize that thalidomide should be reserved for exceptional circumstances because of significant safety risks (including sedation, constipation, peripheral neuropathy, and teratogenicity). Given these limitations, the policy does not recommend Thalomid for routine treatment of Crohn’s disease.

Initial Therapy and Authorization Requirements

Initial therapy requirements

Initial authorization criteria and required trials for non-FDA indications

Multiple Myeloma initial criteria: Patient is >= 18 years AND medication used in combination with at least two other medications; Approve for 1 year.

FDA indication

Discoid/Cutaneous Lupus initial criteria: Patient has tried at least two other medications; Approve for 1 year.

Examples of alternatives listed in policy

Prurigo Nodularis initial criteria: Patient has tried at least two other medications; Approve for 1 year.

Examples of alternatives listed in policy

Continuation and Maintenance Therapy

Continuation therapy notes

Annual revision updated continuation and maintenance use language for certain conditions (e.g., maintenance therapy contexts referenced in literature).

Maintenance/continuation: Policy includes maintenance contexts referenced in the literature (for example, maintenance after infliximab response) but continuation/maintenance use requires condition-specific criteria and documentation; see individual condition sections.

Approvals typically provided for 1 year when criteria met

Prior Medication Trials and Step Therapy Documentation

Requirement	Details
Documentation of prior medication trials is required per indication-specific notes.	For non‑FDA indications listed (for example discoid/cutaneous lupus, prurigo nodularis, recurrent aphthous ulcers), the patient must have tried and had an inadequate response to at least two other medications as specified in each condition note; examples of acceptable prior therapies are provided in each indication section.
For Kaposi sarcoma	Patient must have tried at least one medication (examples include liposomal doxorubicin, paclitaxel, pomalidomide, lenalidomide, imatinib) and have relapsed or refractory disease per the Kaposi sarcoma criteria.
For medulloblastoma (pediatric)	Patient must be < 18 years of age, have recurrent or progressive disease, and the medication must be used as part of the MEMMAT regimen (Thalomid plus listed agents).

Action	Required documentation
Document prior therapies attempted as per condition-specific criteria	Indication sections list the number and examples of prior medications required (e.g., ≥2 prior medications for discoid/cutaneous lupus, prurigo nodularis, and recurrent aphthous ulcers; ≥1 prior medication for Kaposi sarcoma). Include agents tried, durations, and reason for discontinuation or inadequate response.
Include regimen-specific details when applicable	For medulloblastoma, document patient age (<18), recurrence/progression status, and that thalidomide is being used as part of the MEMMAT regimen (list regimen components).
Provide clinical rationale and supportive references when requesting non‑FDA uses	Submit available supporting literature or prior clinical notes that justify use for other supportive-evidence indications; the policy includes example references and notes that receipt of sample product does not satisfy criteria.

Provider Actions, Prior Authorization, and Billing

Prior Authorization

Prior Authorization Required

Prior Authorization is required for benefit coverage of Thalomid. All approvals are provided for the duration(s) specified in the policy criteria (see FDA-approved indications and other uses with supportive evidence).

Prior authorization required for Thalomid (see policy criteria for approved durations).
Approvals provided for durations listed under each indication (e.g., 1 year where specified).

Denial Risk

Coding and Claims Denial Risk

Claims submitted without covered diagnosis or procedure codes referenced in this policy will be denied as not covered. When billing, providers must use the most appropriate and current codes as of the date of submission.

Claims lacking a covered diagnosis/procedure code from this policy = denial as not covered.
Use most current and appropriate billing codes as of the submission date.

Dosage, Duration, and Site of Care Guidance

Billing Rule

Ensure clinically appropriate dosing, duration, and site of care

When coverage is available and medically necessary, ensure dosage, frequency, duration of therapy, and site of care (including home administration) are reasonable, clinically appropriate, supported by evidence, and adjusted based on severity, alternative treatments, and prior response.

Background on Thalomid (thalidomide)

Thalomid (thalidomide) is an immunomodulatory agent with FDA-approved indications that include treatment of erythema nodosum leprosum (ENL) and use in multiple myeloma as part of combination therapy. The agent has supportive evidence for several other dermatologic, oncologic, and rare-disease uses but is associated with important safety concerns (notably teratogenicity and peripheral neuropathy) that limit its use to specified, criteria-based circumstances in this policy.

Key Definitions and Indication Notes

ENL — Erythema nodosum leprosum indication details

IndicationErythema Nodosum Leprosum (ENL): acute treatment of cutaneous manifestations in moderate to severe disease; maintenance therapy to prevent recurrence

Monotherapy noteNot indicated as monotherapy for ENL when moderate to severe neuritis is present

Approval durationApprove for 1 year when criteria met

Therapeutic contextUsed for both acute management of cutaneous ENL and maintenance suppression of recurrence

Multiple Myeloma use — Use in newly diagnosed multiple myeloma

IndicationMultiple myeloma (newly diagnosed) when used in combination with dexamethasone